Supplementary Figure 1 from A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal
posted on 2023-03-31, 17:41authored byGiuseppe Floris, Agnieszka Wozniak, Raf Sciot, Haifu Li, Lori Friedman, Thomas Van Looy, Jasmien Wellens, Peter Vermaelen, Christophe M. Deroose, Jonathan A. Fletcher, Maria Debiec-Rychter, Patrick Schöffski
PDF file - 2344K, Representative images of control tumors from GIST882Ly (A-E) and GIST-DFR (F-J). The H&E staining was shown to illustrate tumor morphology (A, F). Expression of KIT (B, G), ANO1 (C, H), ETV1 (D, I) and CD44 (E, J) were studied to further characterize GIST xenograft models.